Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.12 USD | -2.30% | +11.58% | -36.34% |
05-13 | Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating | MT |
05-09 | Transcript : Coherus BioSciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Sales 2024 * | 261M 355M | Sales 2025 * | 354M 482M | Capitalization | 243M 331M |
---|---|---|---|---|---|
Net income 2024 * | - 0 | Net income 2025 * | -34M -46.27M | EV / Sales 2024 * | 1.96 x |
Net Debt 2024 * | 268M 365M | Net Debt 2025 * | 286M 390M | EV / Sales 2025 * | 1.49 x |
P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
-7.42
x | Employees | 249 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.96% |
Latest transcript on Coherus BioSciences, Inc.
1 day | -2.30% | ||
1 week | +11.58% | ||
Current month | +8.16% | ||
1 month | -1.40% | ||
3 months | -23.19% | ||
6 months | -0.47% | ||
Current year | -36.34% |
Managers | Title | Age | Since |
---|---|---|---|
Denny Lanfear
CEO | Chief Executive Officer | 68 | 10-08-31 |
Bryan Mcmichael
DFI | Director of Finance/CFO | 46 | 21-02-28 |
Chief Tech/Sci/R&D Officer | - | 21-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mark Stolper
BRD | Director/Board Member | 52 | 21-01-04 |
Mats Wahlström
BRD | Director/Board Member | 70 | 11-12-31 |
Ali Satvat
BRD | Director/Board Member | 46 | 14-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.07% | 0 M€ | 0.00% | - | |
0.06% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 2.12 | -2.30% | 1,456,527 |
24-05-16 | 2.17 | -0.46% | 1,261,835 |
24-05-15 | 2.18 | +4.81% | 2,475,129 |
24-05-14 | 2.08 | -0.48% | 2,201,171 |
24-05-13 | 2.09 | +10.00% | 3,629,955 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.34% | 249M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- CHRS Stock